Robert J. Gray

Also affiliated with University of Glasgow

Biochemistry, Genetics and Molecular BiologyMedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.476Author DataRank

Indexed papers

6in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 6 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Papers

Driven by 43 papers — median percentile 0. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Journal of Clinical Oncology(2020)10.1200/jco.19.01866

N/A

3.5DataRank · unranked

102 citations

Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina R. Yanez +14 more

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial

Journal of Clinical Oncology(2023)10.1200/jco.23.00377

N/A

2.3DataRank · unranked

46 citations

Fengmin Zhao, Ju‐Whei Lee, Edward H. Ip, John Devin Peipert, Noah Graham +11 more

Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.3854

N/A

0.864DataRank · unranked

21 citations

Fengmin Zhao, Ju‐Whei Lee, Shu-en Shen, Edward H. Ip, Nathaniel S. O’Connell +12 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0.457DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

Cancer(2021)10.1002/cncr.33992

N/A

0.266DataRank · unranked

4 citations

Santiago Saldana, Kathy D. Miller, Ruth C. Carlos, Ilana F. Gareen, Joseph A. Sparano +9 more

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

JCO Precision Oncology(2024)10.1200/po.24.00327

N/A

0.260DataRank · unranked

4 citations

Opeyemi A. Jegede, David M. Jackman, James A. Zwiebel, Robert J. Gray, Victoria Wang +17 more

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

JCO Precision Oncology(2024)10.1200/po.23.00454

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Helena A. Yu, Lecia V. Sequist, Christine M. Lovly, Edith P. Mitchell +17 more

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

European Journal of Cancer(2022)10.1016/s0959-8049(22)01023-1

N/A

0.104DataRank · unranked

1 citations

Zeyuan Song, Scott Gettinger, Edith P. Mitchell, JJ Wright, Jeff Moscow +14 more

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3087

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray +13 more

Association between allostatic load, symptom burden and mortality in E1A11 trial for myeloma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12102

N/A

0DataRank · unranked

0 citations

Noah Graham, Shaji Kumar, Ju‐Whei Lee, David Cella, Fengmin Zhao +9 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

Blood Cancer Journal(2022)10.1038/s41408-022-00648-y

N/A

0DataRank · unranked

25 citations

Noah Graham, Shaji Kumar, Ju‐Whei Lee, Susanna Jacobus, Matthias Weiss +12 more

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V

European Journal of Cancer(2022)10.1016/s0959-8049(22)01026-7

N/A

0DataRank · unranked

3 citations

Zeyuan Song, A. Poklepovic, Eric A. Collisson, Edith P. Mitchell, James Zweibel +15 more

Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12094

N/A

0DataRank · unranked

0 citations

John Devin Peipert, Vered Stearns, Victor T. Chang, Opeyemi A. Jegede, Edward H. Ip +15 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0DataRank · unranked

3 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study

npj Breast Cancer(2024)10.1038/s41523-024-00622-w

N/A

0DataRank · unranked

13 citations

Robert J. Gray, Habib Rahbar, Christopher Comstock, Judy A. Tjoe, Sunil Badve +5 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

JCO Precision Oncology(2024)10.1200/po-24-00514

N/A

0DataRank · unranked

0 citations

Zihe Song, Andrew Poklepovic, Eric A. Collisson, James A. Zwiebel, Robert J. Gray +14 more

Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments

Cancer(2025)10.1002/cncr.70084

N/A

0DataRank · unranked

2 citations

Shaili Ganatra, Fengmin Zhao, Ju‐Whei Lee, Jessica Roydhouse, Edward H. Ip +13 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0DataRank · unranked

115 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0DataRank · unranked

90 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95

N/A

0DataRank · unranked

1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1073

N/A

0DataRank · unranked

32 citations

Megan Othus, Sandip Pravin Patel, Young Kwang Chae, Kathy D. Miller, Rashmi Chugh +8 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19136

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +9 more

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19132

N/A

0DataRank · unranked

3 citations

John Devin Peipert, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +15 more

Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7004

N/A

0DataRank · unranked

1 citations

Robert J. Gray, Joseph A. Sparano, Ruth C. Carlos, Gelareh Sadigh, Sofia F. Garcia +6 more

Breast cancer patients’ insurance status correlates with their adherence to endocrine therapy: Analysis of ECOG-ACRIN TAILORx trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7041

N/A

0DataRank · unranked

0 citations

Robert J. Gray, Betina R. Yanez, Lynne I. Wagner, Sofia F. Garcia, Joseph A. Sparano +3 more

Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial

Cancer(2021)10.1002/cncr.33527

N/A

0DataRank · unranked

29 citations

Robert J. Gray, Joseph A. Sparano, Betina R. Yanez, Sofia F. Garcia, Lava Timsina +5 more

Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy

Cancer(2021)10.1002/cncr.33939

N/A

0DataRank · unranked

5 citations

Robert J. Gray, Joseph A. Sparano, Amyé Tevaarwerk, Ruth C. Carlos, Betina R. Yanez +6 more

Robert J. Gray

Indexed papers

Top data-sharing exemplar

Papers